KIF18A-IN-2
Modify Date: 2024-01-05 18:23:56
KIF18A-IN-2 structure
|
Common Name | KIF18A-IN-2 | ||
|---|---|---|---|---|
| CAS Number | 2600559-20-2 | Molecular Weight | 534.69 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H34N4O5S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of KIF18A-IN-2KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer[1]. |
| Name | KIF18A-IN-2 |
|---|
| Description | KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 28 nM (KIF18A)[1] |
| In Vivo | KIF18A-IN-2 (compound 23) (100 mg/kg; i.p., single) exhibits a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours[1].Pharmacokinetic Parameters of KIF18A-IN-2 in female CD-1 mice[1]. IP (100 mg/kg) Cmax (μM) 12.6 AUC0-24 (μM·h) 147 C24h (μM) 2.9 PPB (fu) 0.007 Animal Model: Female athymic nude mice (4-7 weeks; injected with human OVCAR-3 HGSOC cells)[1] Dosage: 100 mg/kg Administration: i.p., single Result: Showed a significant and sustained pharmacodynamic response, increasing the number of mitotic cells (pH3 positive cells) in tumor tissues for up to 24 hours. |
| References |
| Molecular Formula | C25H34N4O5S2 |
|---|---|
| Molecular Weight | 534.69 |